ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Injectable Antipsychotics (LAIs) Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-16M17038
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Long acting Injectable Antipsychotics LAIs Market Research Report 2024
BUY CHAPTERS

Global Long-acting Injectable Antipsychotics (LAIs) Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-16M17038
Report
November 2025
Pages:149
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Essential Pharma
Janssen Pharmaceuticals
Qilu Pharmaceutical
Alkermes Pharma Ireland Limited
Lvye Pharmaceutical

Long-acting Injectable Antipsychotics (LAIs) Market

The global Long-acting Injectable Antipsychotics (LAIs) market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.
From a downstream perspective, Schizophrenia accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Long-acting Injectable Antipsychotics (LAIs) leading manufacturers including Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical, etc., dominate supply; the top five capture approximately % of global revenue, with Otsuka Pharmaceutical leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting Injectable Antipsychotics (LAIs) market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Long-acting Injectable Antipsychotics (LAIs) Market Report

Report Metric Details
Report Name Long-acting Injectable Antipsychotics (LAIs) Market
Segment by Type
  • First-generation
  • Second-generation
Segment by Application
  • Schizophrenia
  • Bipolar Disorder
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Long-acting Injectable Antipsychotics (LAIs) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The main players in the Long-acting Injectable Antipsychotics (LAIs) Market are Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical

What are the Application segmentation covered in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The Applications covered in the Long-acting Injectable Antipsychotics (LAIs) Market report are Schizophrenia, Bipolar Disorder, Other

What are the Type segmentation covered in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The Types covered in the Long-acting Injectable Antipsychotics (LAIs) Market report are First-generation, Second-generation

1 Study Coverage
1.1 Introduction to Long-acting Injectable Antipsychotics (LAIs): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 First-generation
1.2.3 Second-generation
1.3 Market Segmentation by Application
1.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Estimates and Forecasts 2020-2031
2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Long-acting Injectable Antipsychotics (LAIs) Sales Estimates and Forecasts 2020-2031
2.4 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Long-acting Injectable Antipsychotics (LAIs) Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 First-generation Market Size by Manufacturers
3.5.2 Second-generation Market Size by Manufacturers
3.6 Global Long-acting Injectable Antipsychotics (LAIs) Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Type (2020-2031)
6.4 North America Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Type (2020-2031)
7.4 Europe Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long-acting Injectable Antipsychotics (LAIs) Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Type (2020-2031)
9.4 Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Otsuka Pharmaceutical
11.1.1 Otsuka Pharmaceutical Corporation Information
11.1.2 Otsuka Pharmaceutical Business Overview
11.1.3 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.1.4 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales by Product in 2024
11.1.6 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales by Application in 2024
11.1.7 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Area in 2024
11.1.8 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
11.1.9 Otsuka Pharmaceutical Recent Developments
11.2 CHEPLAPHARM Arzneimittel GmbH
11.2.1 CHEPLAPHARM Arzneimittel GmbH Corporation Information
11.2.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
11.2.3 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.2.4 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales by Product in 2024
11.2.6 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales by Application in 2024
11.2.7 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Area in 2024
11.2.8 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
11.2.9 CHEPLAPHARM Arzneimittel GmbH Recent Developments
11.3 Alkermes Pharma Ireland Limited
11.3.1 Alkermes Pharma Ireland Limited Corporation Information
11.3.2 Alkermes Pharma Ireland Limited Business Overview
11.3.3 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.3.4 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales by Product in 2024
11.3.6 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales by Application in 2024
11.3.7 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Area in 2024
11.3.8 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
11.3.9 Alkermes Pharma Ireland Limited Recent Developments
11.4 Essential Pharma
11.4.1 Essential Pharma Corporation Information
11.4.2 Essential Pharma Business Overview
11.4.3 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.4.4 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales by Product in 2024
11.4.6 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales by Application in 2024
11.4.7 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Area in 2024
11.4.8 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
11.4.9 Essential Pharma Recent Developments
11.5 Janssen Pharmaceuticals
11.5.1 Janssen Pharmaceuticals Corporation Information
11.5.2 Janssen Pharmaceuticals Business Overview
11.5.3 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.5.4 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales by Product in 2024
11.5.6 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales by Application in 2024
11.5.7 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales by Geographic Area in 2024
11.5.8 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
11.5.9 Janssen Pharmaceuticals Recent Developments
11.6 Indivior UK Limited
11.6.1 Indivior UK Limited Corporation Information
11.6.2 Indivior UK Limited Business Overview
11.6.3 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.6.4 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Indivior UK Limited Recent Developments
11.7 Qilu Pharmaceutical
11.7.1 Qilu Pharmaceutical Corporation Information
11.7.2 Qilu Pharmaceutical Business Overview
11.7.3 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.7.4 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Qilu Pharmaceutical Recent Developments
11.8 Lvye Pharmaceutical
11.8.1 Lvye Pharmaceutical Corporation Information
11.8.2 Lvye Pharmaceutical Business Overview
11.8.3 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Models, Descriptions and Specifications
11.8.4 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Lvye Pharmaceutical Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Long-acting Injectable Antipsychotics (LAIs) Industry Chain
12.2 Long-acting Injectable Antipsychotics (LAIs) Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Long-acting Injectable Antipsychotics (LAIs) Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Long-acting Injectable Antipsychotics (LAIs) Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long-acting Injectable Antipsychotics (LAIs) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long-acting Injectable Antipsychotics (LAIs) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Essential Pharma
Janssen Pharmaceuticals
Qilu Pharmaceutical
Alkermes Pharma Ireland Limited
Lvye Pharmaceutical
List of Tables
 Table 1. Global Long-acting Injectable Antipsychotics (LAIs) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Long-acting Injectable Antipsychotics (LAIs) Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2020-2025) & (K Units)
 Table 8. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Long-acting Injectable Antipsychotics (LAIs) Sales Share by Manufacturers (2020-2025)
 Table 12. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Long-acting Injectable Antipsychotics (LAIs) by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Injectable Antipsychotics (LAIs) as of 2024)
 Table 16. Global Long-acting Injectable Antipsychotics (LAIs) Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Long-acting Injectable Antipsychotics (LAIs) Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base and Headquarters
 Table 19. Global Long-acting Injectable Antipsychotics (LAIs) Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2020-2025) & (K Units)
 Table 23. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2026-2031) & (K Units)
 Table 24. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Long-acting Injectable Antipsychotics (LAIs) ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2020-2025) & (K Units)
 Table 29. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2026-2031) & (K Units)
 Table 30. Long-acting Injectable Antipsychotics (LAIs) High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Long-acting Injectable Antipsychotics (LAIs) ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Long-acting Injectable Antipsychotics (LAIs) Growth Accelerators and Market Barriers
 Table 37. North America Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Long-acting Injectable Antipsychotics (LAIs) Growth Accelerators and Market Barriers
 Table 40. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Long-acting Injectable Antipsychotics (LAIs) Investment Opportunities and Key Challenges
 Table 47. Central and South America Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Otsuka Pharmaceutical Corporation Information
 Table 51. Otsuka Pharmaceutical Description and Major Businesses
 Table 52. Otsuka Pharmaceutical Product Models, Descriptions and Specifications
 Table 53. Otsuka Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Otsuka Pharmaceutical Sales Value Proportion by Product in 2024
 Table 55. Otsuka Pharmaceutical Sales Value Proportion by Application in 2024
 Table 56. Otsuka Pharmaceutical Sales Value Proportion by Geographic Area in 2024
 Table 57. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
 Table 58. Otsuka Pharmaceutical Recent Developments
 Table 59. CHEPLAPHARM Arzneimittel GmbH Corporation Information
 Table 60. CHEPLAPHARM Arzneimittel GmbH Description and Major Businesses
 Table 61. CHEPLAPHARM Arzneimittel GmbH Product Models, Descriptions and Specifications
 Table 62. CHEPLAPHARM Arzneimittel GmbH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. CHEPLAPHARM Arzneimittel GmbH Sales Value Proportion by Product in 2024
 Table 64. CHEPLAPHARM Arzneimittel GmbH Sales Value Proportion by Application in 2024
 Table 65. CHEPLAPHARM Arzneimittel GmbH Sales Value Proportion by Geographic Area in 2024
 Table 66. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
 Table 67. CHEPLAPHARM Arzneimittel GmbH Recent Developments
 Table 68. Alkermes Pharma Ireland Limited Corporation Information
 Table 69. Alkermes Pharma Ireland Limited Description and Major Businesses
 Table 70. Alkermes Pharma Ireland Limited Product Models, Descriptions and Specifications
 Table 71. Alkermes Pharma Ireland Limited Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Alkermes Pharma Ireland Limited Sales Value Proportion by Product in 2024
 Table 73. Alkermes Pharma Ireland Limited Sales Value Proportion by Application in 2024
 Table 74. Alkermes Pharma Ireland Limited Sales Value Proportion by Geographic Area in 2024
 Table 75. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
 Table 76. Alkermes Pharma Ireland Limited Recent Developments
 Table 77. Essential Pharma Corporation Information
 Table 78. Essential Pharma Description and Major Businesses
 Table 79. Essential Pharma Product Models, Descriptions and Specifications
 Table 80. Essential Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Essential Pharma Sales Value Proportion by Product in 2024
 Table 82. Essential Pharma Sales Value Proportion by Application in 2024
 Table 83. Essential Pharma Sales Value Proportion by Geographic Area in 2024
 Table 84. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
 Table 85. Essential Pharma Recent Developments
 Table 86. Janssen Pharmaceuticals Corporation Information
 Table 87. Janssen Pharmaceuticals Description and Major Businesses
 Table 88. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
 Table 89. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
 Table 91. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
 Table 92. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
 Table 93. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) SWOT Analysis
 Table 94. Janssen Pharmaceuticals Recent Developments
 Table 95. Indivior UK Limited Corporation Information
 Table 96. Indivior UK Limited Description and Major Businesses
 Table 97. Indivior UK Limited Product Models, Descriptions and Specifications
 Table 98. Indivior UK Limited Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Indivior UK Limited Recent Developments
 Table 100. Qilu Pharmaceutical Corporation Information
 Table 101. Qilu Pharmaceutical Description and Major Businesses
 Table 102. Qilu Pharmaceutical Product Models, Descriptions and Specifications
 Table 103. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Qilu Pharmaceutical Recent Developments
 Table 105. Lvye Pharmaceutical Corporation Information
 Table 106. Lvye Pharmaceutical Description and Major Businesses
 Table 107. Lvye Pharmaceutical Product Models, Descriptions and Specifications
 Table 108. Lvye Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Lvye Pharmaceutical Recent Developments
 Table 110. Key Raw Materials Distribution
 Table 111. Raw Materials Key Suppliers
 Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 113. Milestones in Production Technology Evolution
 Table 114. Distributors List
 Table 115. Market Trends and Market Evolution
 Table 116. Market Drivers and Opportunities
 Table 117. Market Challenges, Risks, and Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources


List of Figures
 Figure 1. Long-acting Injectable Antipsychotics (LAIs) Product Picture
 Figure 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. First-generation Product Picture
 Figure 4. Second-generation Product Picture
 Figure 5. Global Long-acting Injectable Antipsychotics (LAIs) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Schizophrenia
 Figure 7. Bipolar Disorder
 Figure 8. Other
 Figure 9. Long-acting Injectable Antipsychotics (LAIs) Report Years Considered
 Figure 10. Global Long-acting Injectable Antipsychotics (LAIs) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2020-2031)
 Figure 14. Global Long-acting Injectable Antipsychotics (LAIs) Sales (2020-2031) & (K Units)
 Figure 15. Global Long-acting Injectable Antipsychotics (LAIs) Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 16. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Volume Market Share in 2024
 Figure 18. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. First-generation Revenue Market Share by Manufacturer in 2024
 Figure 21. Second-generation Revenue Market Share by Manufacturer in 2024
 Figure 22. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2020-2031)
 Figure 23. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2020-2031)
 Figure 24. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2020-2031)
 Figure 25. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2020-2031)
 Figure 26. North America Long-acting Injectable Antipsychotics (LAIs) Sales YoY (2020-2031) & (K Units)
 Figure 27. North America Long-acting Injectable Antipsychotics (LAIs) Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) in 2024
 Figure 29. North America Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Type (2020- 2031)
 Figure 30. North America Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 31. North America Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Application (2020-2031)
 Figure 32. North America Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 33. US Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 34. Canada Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 35. Mexico Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 36. Europe Long-acting Injectable Antipsychotics (LAIs) Sales YoY (2020-2031) & (K Units)
 Figure 37. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Europe Top 5 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) in 2024
 Figure 39. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Type (2020-2031)
 Figure 40. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Application (2020-2031)
 Figure 42. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Germany Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 44. France Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 45. U.K. Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 46. Italy Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 47. Russia Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales YoY (2020-2031) & (K Units)
 Figure 49. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Top 8 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) in 2024
 Figure 51. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Type (2020- 2031)
 Figure 52. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 53. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Application (2020-2031)
 Figure 54. Asia-Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Indonesia Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 56. Japan Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 57. South Korea Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 58. China Taiwan Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 59. India Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2031) & (US$ Million)
 Figure 60. Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales YoY (2020-2031) & (K Units)
 Figure 61. Central and South America Long-acting Injectable Antipsychotics (LAIs) Revenue YoY (2020-2031) & (US$ Million)
 Figure 62. Central and South America Top 5 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) in 2024
 Figure 63. Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Type (2021-2031)
 Figure 64. Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Application (2020-2031)
 Figure 66. Central and South America Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 67. Brazil Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 68. Argentina Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 69. Middle East, and Africa Long-acting Injectable Antipsychotics (LAIs) Sales YoY (2020-2031) & (K Units)
 Figure 70. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue YoY (2020-2031) & (US$ Million)
 Figure 71. Middle East and Africa Top 5 Manufacturers Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) in 2024
 Figure 72. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Type (2021-2031)
 Figure 73. South America Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 74. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales Volume (K Units) by Application (2020-2031)
 Figure 75. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 76. GCC Countries Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 77. Turkey Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 78. Egypt Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 79. South Africa Long-acting Injectable Antipsychotics (LAIs) Revenue (2020-2025) & (US$ Million)
 Figure 80. Long-acting Injectable Antipsychotics (LAIs) Industry Chain Mapping
 Figure 81. Regional Long-acting Injectable Antipsychotics (LAIs) Manufacturing Base Distribution (%)
 Figure 82. Global Long-acting Injectable Antipsychotics (LAIs) Production Market Share by Region (2020-2031)
 Figure 83. Long-acting Injectable Antipsychotics (LAIs) Production Process
 Figure 84. Regional Long-acting Injectable Antipsychotics (LAIs) Production Cost Structure
 Figure 85. Channels of Distribution (Direct Vs Distribution)
 Figure 86. Bottom-up and Top-down Approaches for This Report
 Figure 87. Data Triangulation
 Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Long Acting Injectable LAI Antipsychotic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Long acting Injectable Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Long Acting Schizophrenia Drug Market Research Report 2024
Global Long acting Antipsychotic Market Research Report 2024
Global Psychiatric Long acting Injection Market Research Report 2024
Antipsychotics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Paliperidone Palmitate Injection Market Research Report 2024
Global Olanzapine Tablets Market Research Report 2024
Global Ziprasidone Mesylate for Injection Market Research Report 2024
Global Risperidone Microspheres for Injection Market Research Report 2024
Global Antipsychotic Medications Market Research Report 2024
Neuroleptics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ziprasidone Drugs Market Research Report 2024
Global Risperidone API Market Research Report 2025
Global Antipsychotic Drug Market Research Report 2024
Global Quetiapine Fumarate Market Insights Forecast to 2030
Global Long Acting Contraceptive Pills Market Research Report 2024
Global Clozapine Oral Suspension Market Research Report 2024
Global Risperidone Market Research Report 2024
Global Chlorpromazine Hydrochloride Tablets Market Research Report 2025

RELATED REPORTS

Global Levothyroxine Sodium Tablets Hormone Medication Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25N19924
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24B19783
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20305
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12S20176
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions